BioWorld MedTech

April 20, 2016

JNJ kicks off 2016 with strong Q1, but device biz may get a Band-Aid

Johnson & Johnson(J&J) reported a strong first quarter overall, beating quarterly earnings forecasts on prescription drug revenue, but the company's medical device business has seen better days. Read More

The new kid on China's block, ophthalmology market enjoys boom

Ontario startup offers pragmatic tool for low cost hip replacement

CMS skeptical about new tech add-on for Edwards Intuity valve

Other news to note

Financings

Product Briefs

Keeping you up to date on recent developments in oncology

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....